.png){kind=icon}
.png){kind=icon}
Return
Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies
.png){kind=icon}
OA
AI
D
M
D
J
M
J
L
R
J
J
J
S
L
G
D
DOI：10.1186/s13045-026-01837-z.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En
Journal
J
IF:
40.4
Papers:
67
Citations:
0